Objective: To determine apolipoprotein E (APOE)-ε4 and -ε2 frequencies and risk of mild cognitive impairment (MCI) and dementia in Shanghai, China. Methods: A total of 34 MCI and 34 dementia cases were recruited from an urban Memory Disorders Clinic and 32 controls were recruited from a residential community served by the clinic. Apolipoprotein E was genotyped using standard methods. Results: Among controls, frequencies were ε2, 0.11; ε3, 0.84; and ε4, 0.05; among MCI, 0.05, 0.77, and 0.18; and for dementia, 0.02, 0.84, and 0.15, respectively. In education-adjusted models, the odds ratio (OR) = 5.6 for dementia (95% CI = 1.09-29.3) and 4.7 for MCI (95% CI = 0.90-25.2) associated with any ε4 allele. The ε2 allele was inversely associated with dementia (OR = 0.12, 95% CI = 0.013-0.997) and MCI (OR = 0.38, 95% CI = 0.08-1.61). Conclusions: APOE-ε4 increases and -ε2 decreases the risk of dementia vs normal cognition. Similar trends were observed for amnestic mild cognitive impairment (aMCI).
Mak YT, Chiu H., Woo J., et al. Apolipoprotein E genotype and Alzheimer’s disease in Hong Kong elderly Chinese. Neurology. 1996;46(1):146-149.
2.
Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta-Analysis Consortium. JAMA. 1997;278(16):1349-1356.
3.
Katzman R., Zhang MY, Chen PJ, et al. Effects of apolipoprotein E on dementia and aging in the Shanghai Survey of Dementia. Neurology. 1997;49(3):779-785.
4.
Zhang JG, Yang JG, Lin X., et al. Apolipoprotein E ε4 allele is a risk factor for late-onset Alzheimer’s disease and vascular dementia in Han Chinese. Int J Geriatr Psychiatry. 2001;16(4):436-441.
5.
Bennett DA, Wilson RS, Schneider JS, et al. Apolipoprotein E ε4 allele, AD pathology, and the clinical expression of Alzheimer’s disease. Neurology. 2003;60(2):246-252.
6.
Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late-onset families. Science . 1993;261(5123):921-923.
7.
Murrell JR, Price B., Lane KA, et al. Association of apolipoprotein E genotype and Alzheimer disease in African Americans. Arch Neurol. 2006;63(3):431-434.
8.
Borenstein A. , Mortimer JA, Wu Y., et al. Apolipoprotein E and cognition in population-based samples of African Americans and Whites . Ethnicity and Disease. 2006;16(1):9-15.
9.
Wilson RS, Bienias JL, Berry-Kravis E., Evans DA, Bennett DAThe apolipoprotein E epsilon 2 allele and decline in episodic memory . J Neurol Neurosurg Psych.2002;73(6):672-677.
10.
Corder EH, Saunders AM, Risch NJ, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Gen. 1994;7(2):180-184.
11.
Lung FW, Yen YC, Chou LJ, Hong CJ, Wu CKThe allele interaction between apolipoprotein ε2 and ε4 in Taiwanese Alzheimer’s disease patients. Acta Psychiatr Scand. 2005;111(1):38-43.
12.
Davignon J. , Gregg RE, Sing CFApolipoprotein E polymorphism and atherosclerosis . Arteriosclerosis. 1988 ;8(1):1-21.
13.
Chen HH, Hu CJThe genetic studies of dementias in Taiwan. Acta Neurol Taiwan . 2006;15(1):60-63.
14.
Lai CL, Tai CT, Lin SR, Lin RT, Yang YH, Liu CK. Apolipoprotein E in Taiwan Chinese patients with dementia . Dement Geriatr Cogn Disord. 2003;16(4):208-211.
15.
Petersen RCMild Cognitive Impairment: Aging to Alzheimer’s disease. New York, NY: Oxford University Press; 2003:238.
16.
Reiman EM, Chen K., Alexander GE, et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer’s dementia. Proc Natl Acad Sci. 2004;101(1):284-289.
17.
Okello A., Koivunen J., Edison P., et al. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology.2009 ;73(10):744-745.
18.
Yaffe K., Petersen RC, Lindquist K., Kramer J., Miller B.Subtype of mild cognitive impairment and progression to dementia and death . Dement Geriatr Cogn Disord. 2006;22(4):312-319.
19.
Teng EL, Hasegawa K., Homma A., et al. The Cognitive Abilities Screening Instrument (CASI): a practical test for cross-cultural epidemiologic studies of dementia. Int Psychogeriatr. 1994;6(1):45-56.
20.
Wechsler D.WAIS-R Manual: Wechsler Adult Intelligence Scale-Revised. New York, NY: Psychological Corporation; 1981.
21.
Gauthier L. , Dehaut F., Joanette Y.The Bells test: a quantitative and qualitative test for visual neglect. Int J Clin Neuropsychol . 1989;11(2):49-54.
22.
Wechsler D.Wechsler Memory Scale-Revised Manual. San Antonio: Psychological Corporation; 1987.
23.
Rey A.L-examen psychologique dans les cas d’encephalopathie traumatique . Arch Psychologie. 1941;28:286-340.
24.
Golden CJStroop Color and Word Test. Chicago, IL: Stoelting Company; 1978.
25.
Schmidt M.Rey Auditory Verbal Learning Test. A Handbook. Los Angeles, CA: Western Psychological Services; 1996.
26.
Reitan R.Validity of the Trail Making Test as an indicator of organic brain damage . Percept Motor Skills. 1958;8:271-276.
27.
Rouleau I., Salmon DP, Butters N., Kennedy C., McGuire K.Quantitative and qualitative analyses of clock drawings in Alzheimer’s and Huntington’s disease. Brain Cogn. 1992;18(1):70-87.
American Psychiatric Association.Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington DC: APA; 2000.
31.
McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan EM Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology . 1984;34(7):939-944.
32.
Román GC, Tatemichi TK, Erkinjuntti T., et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology. 1993;43(2): 250-260.
33.
Petersen RC , Doody R., Kurz A., et al. Current concepts in mild cognitive impairment. Arch Neurol. 2001;58(12):1985-1992.
34.
Petersen RCMild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256(3):183-194.
35.
Guo Q., Lu CZ, Hong Z.Reliability and validity of auditory verbal learning test on Chinese elderly patients. Chinese Mental Health J. 2001;15(1):13-15.
36.
Guo Q., Sun YM, Yu PM, Hong Z., Lu CZNorms for Auditory Verbal Learning Test in the normal aged in Chinese community . Chinese J Clin Psychol. 2007;15(2):132-135.
37.
Emi M., Wu LL, Robertson MA, et al. Genotyping and sequence analysis of apolipoprotein E isoforms . Genomics. 1988;3(4): 373-379.
38.
Hixson JE, Vernier DTRestriction isotyping of human apolipoprotein E by gene amplification and cleavage with Hhal. J. Lipid Res.1990 ;31:545-548.
39.
SAS Institute.SAS System for Microsoft Windows (version 9). Cary, NC: SAS Institute Inc; 2003.
40.
Bertram L., Lill CM, McQueen MB, Schieide BMM, Zauft U.Alzgene: Published AD candidate genes. www.alzgene.org/meta.asp?geneID=83. Alzheimer Research Forum, www.alzforum.org, 2009. Accessed August 17, 2009.
41.
Wang QS, Tian L., Huang YL, Qin S., He LQ, Zhou JNOlfactory identification and apolipoprotein E ε4 allele in mild cognitive impairment. Brain Res. 2002;951(1):77-81.
42.
Lehtovirta M., Helisalmi S., Mannermaa A., et al. Apolipoprotein E polymorphism and Alzheimer’s disease in Eastern Finland. Neurosci Lett . 1995;185(1):13-15.
43.
Chartier-Harlin MC, Parfitt M., Legrain S., et al. Apolipoprotein E ε4 allele as a major risk factor for sporadic early and late-onset forms of Alzheimer’s disease: analysis of the 19q132 chromosomal region. Hum Mol Gen. 1994;3(4):569-574.
44.
Ehnholm C., Lukka M., Kuusi T., Nlkklla E., Utermann Q. Apolipoprotein E polymorphism in the Finnish population: gene frequencies and relation to lipoprotein concentrations. J Lipid Res. 1986;27(3):227-235.
45.
Tsai MS, Tangalos EG, Petersen RC, et al. Apolipoprotein E: risk factor for Alzheimer Disease. Am J Hum Gen. 1994;54(4): 643-649.
46.
Kukull WA, Schellenberg GD, Bowen JD, et al. Apolipoprotein E in Alzheimer’s Disease risk and case detection: a case-control study. J Clin Epidemiol. 1996;49(10):1143-1148.
47.
Rebeck GW, Kindy M., LaDu MJApolipoprotein E and Alzheimer’s disease: the protective effects of ApoE2 and E3. Journal of Alzheimer’s Disease. 2002;4(3):145-154.
48.
Mortimer JA , Snowdon DA, Markesbery WRThe effect of APOE-ε4 on dementia is mediated by Alzheimer neuropathology. Alzheimer Dis Assoc Disord.2009;23(2):152-157.
49.
Wu YN, Zhang JW, Zhang ZX, Qu QM, Chen D.An association analysis of apolipoprotein E genotypes with Alzheimer’s disease in Chinese population. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2001;23(5):450-454.
50.
Huang HM, Kuo YM, Ou HC, Lin CC, Chuo LJ. Apolipoprotein E polymorphism in various dementias in Taiwan Chinese population. Journal of Neur Transm. 2002;109(11):1415-1421.
51.
Lam LC, Tang NL, Ma SL, et al. Apolipoprotein episolon-4 allele and the two-year progression of cognitive function in Chinese subjects with late-onset Alzheimer’s disease. Am J Alzheimer’s Dis Other Demen. 2006;21(2):92-99.
52.
Liu HC, Hong CJ, Wang SJ, et al. ApoE genotype in relation to AD and cholesterol: a study of 2,326 Chinese adults. Neurology. 1999;53(5):962-966.
53.
Qiu C., Kivipelto M., Agüero-Torres H., Winblad B., Fratiglioni L.Risk and protective effects of the APOE gene towards Alzheimer’s disease in the Kungsholmen project: variation by age and sex. J Neurol Neurosurg Psych.2004;75(6):828-833.
54.
Berlau DJ, Corrada MM, Head E., Kawas CHAPOE ε2 is associated with intact cognition by increased Alzheimer pathology in the oldest old. Neurology.2009 ;72(9):829-834.
55.
Poirier J.Apolipoprotein E.represents a potent gene-based therapeutic target for the treatment of sporadic Alzheimer’s disease. Alzheimer’s Dementia.2008;4(1):S91-S97.
56.
Holtzman DMIn vivo effects of ApoE and clusterin on amyloidβ metabolism and neuropathology. J Mol Neurosci.2004;23(3): 247-254.
57.
Greenberg SM , Rebeck GW, Vonsattel JPG, Gomez-Isla T., Hyman BTApolipoprotein E e4 and cerebral hemorrhage associated with amyloid angiopathy. Ann Neurol.1995;38(2):254-259.
58.
Strittmatter WJ, Roses ADApolipoprotein E and Alzheimer’s disease . Annu Rev Neurosci. 1996;19:53-57.
59.
Lahoz C., Schaefer EJ, Cupples LA, et al. Apolipoprotein E genotype and cardiovascular disease in the Framingham Heart Study. Atherosclerosis. 2001 ;154(3):529-537.
60.
Wang PN, Lirng JF, Lin KN, Chang FC, Liu HCPrediction of Alzheimer’s disease in mild cognitive impairment: a prospective study in Taiwan. Neurobio Aging. 2006;27(12): 1797-1806.
